» Articles » PMID: 35649611

Clinicodemographic Profile and Predictors of Poor Outcome in Hospitalised COVID-19 Patients: a Single-centre, Retrospective Cohort Study from India

Overview
Journal BMJ Open
Specialty General Medicine
Date 2022 Jun 1
PMID 35649611
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Primary objective was to study the clinicodemographic profile of hospitalised COVID-19 patients at a tertiary-care centre in India. Secondary objective was to identify predictors of poor outcome.

Setting: Single centre tertiary-care level.

Design: Retrospective cohort study.

Participants: Consecutively hospitalised adults patients with COVID-19.

Primary And Secondary Outcome Measures: Primary outcome variable was in-hospital mortality. Covariables were known comorbidities, clinical features, vital signs at the time of admission and on days 3-5 of admission, and initial laboratory investigations.

Results: Intergroup differences were tested using χ or Fischer's exact tests, Student's t-test or Mann-Whitney U test. Predictors of mortality were evaluated using multivariate logistic regression model. Out of 4102 SARS-CoV-2 positive patients admitted during 1-year period, 3268 (79.66%) survived to discharge and 834 (20.33%) died in the hospital. Mortality rates increased with age. Death was more common among males (OR 1.51, 95% CI 1.25 to 1.81). Out of 261 cases analysed in detail, 55.1% were in mild, 32.5% in moderate and 12.2% in severe triage category. Most common clinical presentations in the subgroup were fever (73.2%), cough/coryza (65.5%) and breathlessness (54%). Hypertension (45.2%), diabetes mellitus (41.8%) and chronic kidney disease (CKD; 6.1%) were common comorbidities. Disease severity on admission (adjusted OR 12.53, 95% CI 4.92 to 31.91, p<0.01), coagulation defect (33.21, 3.85-302.1, p<0.01), CKD (5.67, 1.08-29.64, p=0.04), high urea (11.05, 3.9-31.02, p<0.01), high prothrombin time (3.91, 1.59-9.65, p<0.01) and elevated ferritin (1.02, 1.00-1.03, p=0.02) were associated with poor outcome on multivariate regression. A strong predictor of mortality was disease progression on days 3-5 of admission (adjusted OR 13.66 95% CI 3.47 to 53.68).

Conclusion: COVID-19 related mortality in hospitalised adult patients at our center was similar to the developed countries. Progression in disease severity on days 3-5 of admission or days 6-13 of illness onset acts as 'turning point' for timely referral or treatment intensification for optimum use of resources.

Citing Articles

Evaluation of candidemia cases in the intensive care unit of a tertiary training hospital during the period of COVID-19 pandemic.

Karadag F, Engin D, Buber A, Gormus T, Arslan E, Cetin A BMC Infect Dis. 2025; 25(1):288.

PMID: 40021959 PMC: 11869554. DOI: 10.1186/s12879-025-10688-x.


The association between mortality due to COVID-19 and coagulative parameters: a systematic review and meta-analysis study.

Abdollahi A, Nateghi S, Panahi Z, Inanloo S, Salarvand S, Pourfaraji S BMC Infect Dis. 2024; 24(1):1373.

PMID: 39623325 PMC: 11610108. DOI: 10.1186/s12879-024-10229-y.


Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022.

Shen J, Li J, Lei Y, Chen Z, Wu L, Lin C Heliyon. 2024; 10(10):e30955.

PMID: 38774317 PMC: 11107250. DOI: 10.1016/j.heliyon.2024.e30955.


Role of Hematological Parameters in the Grading of COVID-19 and a Model to Predict the Outcome in Inpatients.

Kumar Y, Kumari A, Kumar T, Jha K, Zabihullah M Cureus. 2023; 15(9):e45276.

PMID: 37846240 PMC: 10576849. DOI: 10.7759/cureus.45276.


Association of serum ferritin with severity and clinical outcome in COVID-19 patients: An observational study in a tertiary healthcare facility.

Kurian S, Mathews S, Paul A, Viswam S, Kaniyoor Nagri S, Miraj S Clin Epidemiol Glob Health. 2023; 21:101295.

PMID: 37012977 PMC: 10060024. DOI: 10.1016/j.cegh.2023.101295.


References
1.
Pan H, Peto R, Henao-Restrepo A, Preziosi M, Sathiyamoorthy V, Abdool Karim Q . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020; 384(6):497-511. PMC: 7727327. DOI: 10.1056/NEJMoa2023184. View

2.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A . Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16):1574-1581. PMC: 7136855. DOI: 10.1001/jama.2020.5394. View

3.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

4.
. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285):1637-1645. PMC: 8084355. DOI: 10.1016/S0140-6736(21)00676-0. View

5.
. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study. Lancet. 2021; 397(10288):1885-1894. PMC: 8137309. DOI: 10.1016/S0140-6736(21)00441-4. View